Abstract
Attention deficit hyperactivity disorder (ADHD) is a neurodevelopmental condition that often persists into adulthood, contributing to a challenging trajectory characterised by increased rates of psychiatric comorbidity. Contrary to previous assumptions, the clinical course of ADHD in adulthood is characterised by dynamic changes influenced by stimulant treatment. To improve the precision of treatment, the identification of a predictive neuroimaging biomarker would be of great clinical importance.
In this study, we explore the potential of seed-based functional connectivity (FC) as a predictive tool for assessing the clinical course of ADHD symptoms. We conducted a longitudinal follow-up study of 54 adult ADHD patients who underwent magnetic resonance imaging (MRI) using a 3 Tesla scanner. All patients received stimulant treatment during an initial run-in period. After an average of three years, only subjective responders continued treatment (n=34), while subjective non-responders discontinued medication (n=20). We reassessed patients after three years of treatment to 1) evaluate the prediction of individual outcome by baseline fMRI and 2) to investigate differences in prediction by baseline fMRI depending on long-term treatment vs. discontinuation.
Our investigation focused on determining whether a relationship could be established between resting-state FC of the nucleus accumbens (NAc) and the trajectory of symptom development, as well as identifying possible differences in FC between individuals who had been on long-term stimulant treatment and those who had not used stimulants at the time of follow-up.
In general, reduced FC between the NAc and the default mode network (DMN) was associated with initially higher symptom burden, whereas patterns of improvement correlated with reduced FC between the NAc and the salience network (SN).
Comparatively, higher FC between the NAc and the SN was associated with better symptom outcomes in patients receiving long-term stimulant medication, whereas lower FC between the NAc and the SN was correlated with a more favourable prognosis in non-responders.
Our prospective fMRI study suggests that functional connectivity between the dopaminergic reward circuitry and the SN, especially the insula, is predictive of better ADHD symptom outcomes. This work highlights the potential of dopaminergic functional connectivity as a prognostic factor in ADHD. While future research with larger samples and longer follow-up is warranted, our study highlights the role of the NAc in the prognosis of ADHD.
Competing Interest Statement
AR received speaker and consultation fees from Boehringer Ingelheim GmbH COMPASS, Janssen Pharmaceuticals, LivaNova USA, Inc., Medice, Sage Therapeutics, Inc., and Shire within the last three years. OG received speaker and consultation fees from Boehringer-Ingelheim and Takeda within the last three years. AZ and JL report no conflicts of interest.
Funding Statement
Financial support for this study was received from the European Union Horizon 2020 research and innovation program under grant agreement 667302: Comorbid Conditions of ADHD (CoCA) as well as the Deutsche Forschungsgemeinschaft (DFG grant 445498183, Oliver Grimm).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics committee of the Faculty of Medicine, University Hospital, Goethe University, Frankfurt am Main age ethical approval for this work. (Decision number 256/16)
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos